Patents by Inventor Shenghua Xie

Shenghua Xie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEK293T CELL STRAIN HAVING HIGH DISPERSIBILITY AND SCREENING METHOD THEREFOR
    Publication number: 20240101964
    Abstract: Provided are a HEK293T cell strain having high dispersibility and a screening method therefor. Specifically, the present application relates to a method for screening a HEK293T cell strain suitable for serum-free suspension culture, a cell strain screened by using the method, and a method for producing a viral vector by using the cell strain.
    Type: Application
    Filed: December 28, 2021
    Publication date: March 28, 2024
    Applicant: Jiangsu Genscript Probio Biotech Co., Ltd.
    Inventors: Chen Guo, Shenghua Xie, Chunling Xuan, Erjing Hui, Rongna Ding
  • Use of human NLK gene and associated drugs thereof
    Patent number: 9334502
    Abstract: The present invention discloses the use of a human NLK gene and associated drugs thereof. The present invention discloses the use of the NLK gene for tumor treatment, tumor diagnosis and drug preparation. The present invention further constructs an isolated molecule that attenuates expression of the NLK gene of tumor cells, cells comprising the isolated molecule and a NLK interference lentivirus, and discloses the use thereof as well. The isolated molecule or the NLK interference lentivirus that attenuates expression of the NLK gene provided in the present invention can specifically attenuate expression of the human NLK gene, especially the lentivirus, can effectively infect target cells, efficiently inhibit the expression of the NLK gene in target cells, and inhibit the growth of tumor cells, thus has great significance in tumor treatment.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: May 10, 2016
    Assignee: SHANGHAI GENECHEM CO., LTD
    Inventors: Haixiong Han, Xiangying Zhu, Qin Sun, Xuefeng Gu, Shenghua Xie, Yang Li, Yangsheng Jin, Honghua Qu, Yueqiong Cao
  • USE OF HUMAN NLK GENE AND ASSOCIATED DRUGS THEREOF
    Publication number: 20150005370
    Abstract: The present invention discloses the use of a human NLK gene and associated drugs thereof. The present invention discloses the use of the NLK gene for tumor treatment, tumor diagnosis and drug preparation. The present invention further constructs an isolated molecule that attenuates expression of the NLK gene of tumor cells, cells comprising the isolated molecule and a NLK interference lentivirus, and discloses the use thereof as well. The isolated molecule or the NLK interference lentivirus that attenuates expression of the NLK gene provided in the present invention can specifically attenuate expression of the human NLK gene, especially the lentivirus, can effectively infect target cells, efficiently inhibit the expression of the NLK gene in target cells, and inhibit the growth of tumor cells, thus has great significance in tumor treatment.
    Type: Application
    Filed: January 18, 2012
    Publication date: January 1, 2015
    Applicant: SHANGHAI GENECHEM CO., LTD
    Inventors: Haixiong Han, Xiangying Zhu, Qin Sun, Xuefeng Gu, Shenghua Xie, Yang Li, Yangsheng Jin, Honghua Qu, Yueqiong Cao